OMEROS CORP Deferred Tax Liabilities, Gross
OMEROS CORP (OMER) had Deferred Tax Liabilities, Gross of $34.78 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-31
- 2025-12-31: Deferred Tax Liabilities, Gross $34.78M.
- 2024-12-31: Deferred Tax Liabilities, Gross $39.61M.
- 2023-12-31: Deferred Tax Liabilities, Gross $43.26M.
- 2022-12-31: Deferred Tax Liabilities, Gross $40.16M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $34.78M 10-K · filed 2026-03-31 | |
| 2024-12-31 | $39.61M 10-K · filed 2026-03-31 | |
| 2023-12-31 | $43.26M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $40.16M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $48.78M 10-K · filed 2023-03-13 | |
| 2020-12-31 | $24.61M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $17.56M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $12.71M 10-K · filed 2020-03-02 | $12.86M 10-K · filed 2019-03-01 |
| 2017-12-31 | $10.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |